Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine

INTRODUCTION: Respiratory syncytial virus (RSV) can cause lower respiratory tract disease in infants and elderly populations. Despite decades of research, there remains no safe and approved RSV vaccine. Previously, we showed that an RSV G glycoprotein subunit vaccine candidate with a single point mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergeron, Harrison C., Murray, Jackelyn, Juarez, Maria G., Nangle, Samuel J., DuBois, Rebecca M., Tripp, Ralph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338877/
https://www.ncbi.nlm.nih.gov/pubmed/37457705
http://dx.doi.org/10.3389/fimmu.2023.1215323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338877/
https://www.ncbi.nlm.nih.gov/pubmed/37457705
http://dx.doi.org/10.3389/fimmu.2023.1215323

Ejemplares similares